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Abstract: The rate of reporting of childhood Churg-Strauss
syndrome (CSS) has increased lately because of either increased
awareness to the disease or a real increase in incidence. It is defined as
one of the antineutrophil cytoplasmic antibodyYassociated vasculi-
tides, but the antineutrophil cytoplasmic antibody positivity is less
reported in pediatric cases. The cause of CSS remains unknown.
Several lines of evidence suggest genetic predisposition, which may
entail inherited tendency to dysregulation of the cellular immune
system. With the addition of leukotriene receptor antagonists to the
treatment regimen of asthma, an association to CSS was presumed.
However, the nature of this relationship remains to be elucidated. In
addition, some environmental factors seem to provoke transient
effects that resemble the disease. Patients’ symptoms are defined by
various degrees of eosinophilic inflammation and necrotizing
vasculitis, which may affect any organ. Three clinical stages have
been described in the clinical evolution of CSS: prodromal phase
involving allergic rhinitis and asthma (usually without family history
of atopy), a second phase that involves peripheral eosinophilia and
eosinophilic tissue infiltration, and the hallmark of the final phase is
systemic vasculitis. Pulmonary disease is a central feature of pediatric
CSS, but other manifestations include skin lesions, testicular pain,
hypertension, seizures, and nephropathy. More subtle presentations in
children include cervical lymphadenopathy, acute abdominal pain,
deep venous thrombosis, oral ulceration, multiple colonic ulcers,
chorea, bilateral optic neuropathy, and retinal artery occlusions.
Churg-Strauss syndrome patients usually respond well to corticoster-
oid therapy. Several trials reported additional benefit from cyclopho-
sphamide, azathioprine, and methotrexate, whereas the therapeutic
effects of etanercept, plasma exchange, and intravenous immunoglo-
bulin therapy are controversial. The relapse rate is approximately 25%
to 30%, but corticosteroids have significantly increased survival,
which now approaches greater than 75% at 5 years. However, there is
limited information about survival or long-term outcome in
childhood.
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DEFINITION
This disease was first described in 1951 by Jacob Churgand Lotte Strauss as a syndrome consisting of asthma,
eosinophilia, fever, and vasculitis of various organ systems.
Their report was based on autopsy data and described
diffuse vasculitis and extravascular granulomas with
eosinophilic cores.1 Churg-Strauss syndrome (CSS) is
now defined as one of the antineutrophil cytoplasmic
antibody (ANCA)Yassociated vasculitides. The predilection of
disease manifestations for the respiratory tract, preferred
affliction of small vessels including capillaries, and the
frequent occurrence of ANCAs justify this grouping together
with Wegener granulomatosis and microscopic polyangiitis.
However, the allergic background in which the vasculitis
presents, typically characterized by asthma and prominent
peripheral blood and tissue eosinophilia, renders it unique
among the primary systemic vasculitis syndromes.2
EPIDEMIOLOGY
The incidence of CSS in adults is estimated at 2.4 per
million per year.3 Because of its rarity, the incidence of the
disease in the pediatric age group is unknown. It is conceivable
that patients may go undiagnosed because of the lack of
specificity, low index of suspicion, and invasiveness involved
with pathological confirmation.4 Before 1999, only 10 cases of
childhood CSS (4Y16 years) had been reported.5 The rate of
reporting has increased lately because of either increased
awareness to the disease or a real increase in incidence caused
by hypersensitivity to drugs or other environmental agents.
Not less than 15 pediatric cases have been cited in literature
during the past 8 years.4,6Y18 The youngest reported patients
with CSS were 2 years old.13,19
Few data are available regarding racial variations in
occurrence or severity of manifestations. It has been suggested
that CSS shares with other systemic vasculitides the tendency
toward greater prevalence in whites.20 Literature reveals that a
significant number of reports are arising from Japan,9,12,15
suggesting a possible geographic or ethnic predominance.4
In adults, males are slightly more likely than females to
develop the syndrome.21 This does not seem to apply to
pediatric CSS.
PATHOGENESIS
Churg-Strauss syndrome remains a rare disease with a
poorly understood pathogenesis. No data have been reported
regarding the role of immune complexes or cell-mediated
mechanisms in this disease, although autoimmunity is evident
by the presence of hypergammaglobulinemia, rheumatoid
factor, and ANCA.21
Antineutrophil cytoplasmic antibodies (ANCAs) with
perinuclear staining pattern (p-ANCAs) are detected. Pheno-
typically, ANCA-positive and ANCA-negative CSS might
differ. The association of ANCA positivity with clinical
symptoms that indicate inflammation and necrosis of small
vessels might characterize a predominantly vasculitic pat-
tern.22 The ANCAs may promote polymorphonuclear cell
adherence to vascular endothelial cells.20 In vitro, ANCAs can
further activate primed neutrophils to release reactive oxygen
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species and lytic enzymes, and in conjunction with neutro-
phils, can damage and lyse endothelial cells.23 An independent
or adjuvant role in this activation may be played by tumor
necrosis factor (TNF).20
It was shown that stimulated peripheral blood mono-
nuclear cells from patients with CSS secrete significantly
increased amounts of interleukin 5 (IL-5) compared with
healthy controls, suggesting that IL-5 contributes substantially
to the development of eosinophilia in CSS. Variations in the
balance between TH1 and TH2 cytokines at different disease
stages could contribute to the distinct clinical courses seen in
patients with CSS, which can range from prominent TH1-
mediated generalized vasculitis and granulomatous inflamma-
tion on 1 end of the spectrum to TH2-mediated systemic
hypereosinophilia on the other.24 Occasionally, CD20+ B
lymphocytes are found in the inflammatory exudate, and
deposits of immunoglobulin G (IgG), IgE, and C3d may be
detected.25 Cytokines undoubtedly participate in this auto-
immune process. Patients with CSS have markedly increased
serum levels of interferon alfa and IL-2 and moderate
increases of TNF-> and IL-1A similar to those observed in
polyarteritis nodosa. Elevations of serum IL-6 concentrations
have been shown to precede the rise in serum rheumatoid
factors that may accompany the onset of an exacerbation of
Churg-Strauss vasculitis in adults.20 Soluble CD95, which was
identified as a survival factor for eosinophils rescuing
eosinophils from apoptosis in vitro, was found overexpressed
in CSS, which may suggest that it may be mechanistically
involved in the disease.26
PATHOLOGY
Patients’ symptoms are defined by various degrees of
eosinophilic inflammation and necrotizing vasculitis, which
may affect any organ.27 The vasculopathy of CSS is
predominantly an arteriopathy tending to affect small- and
medium-sized arteries much more than arterioles, veins, or
capillaries. This predilection also is found in polyarteritis
nodosa and some other conditions. However, the predomi-
nance of eosinophils sets CSS apart from these other
conditions. Epithelioid and giant cells also are found in the
inflammatory exudate of patients with CSS. The inflammatory
arteriopathy evolves into granulomatous fibrinoid necrosis of
the vascular media. The granulomatous material surrounds
altered vascular elastic fibers, collagen, and acellular pigmen-
ted debris, which is helpful in pathologically distinguishing 1
form of granulomatous vasculitis from another. Churg-Strauss
syndrome is associated with red collagenolytic granulomas.20
The number of reported childhood cases remains too
small for adequate comparisons between the histological
features of adult and childhood disease.4 Specific pulmonary
histological findings in pediatric CSS have been described
only once, briefly, in a report describing granulomas and
angiitis with focal necrosis and eosinophilic infiltration in a
14-year-old adolescent boy.28 Lung biopsies from 2 patients
showed aggregates of intra-alveolar eosinophils, Beosinophilic
abscesses^ constituting eosinophilic pneumonia. The biopsy
specimen of one of them revealed extravascular microgranu-
lomas filled with eosinophils and their breakdown products.4
These changes were described in the original report of CSS by
Churg and Strauss,1 and although not consistently found in
adult CSS, they are thought to be specific for the disease.
ETIOLOGY
The cause of CSS remains unknown. Several lines of
evidence suggest genetic predisposition, which may entail
inherited tendency to dysregulation of the cellular immune
system.20 Recent studies have demonstrated primary genetic
causes for hypereosinophilia.29 There is significant clinical
overlap between the hypereosinophilic syndromes and CSS. It
is possible that primary genetic disorders may tend especially
to underlie disease with early (childhood) presentations.4
Myeloperoxidase (MPO)-directed ANCAs that are found in
patients with Churg-Strauss disease are also found in
microscopic polyangiitis. It was suggested that a mutation
in exon 11 of the CD18 gene may be permissive for the
elaboration of anti-MPO antibodies in either condition.20
With the recent addition of leukotriene receptor
antagonists (LRAs) to the treatment regimen of asthma, an
association to CSS was presumed. The association of CSS
with LRAs therapy is found in perhaps half of the cases, and
the addition of those drugs was made within 3 months before
the CSS manifestations in three quarters of these patients.30
However, the nature of this relationship remains to be
elucidated. The occurrence of CSS in asthmatic patients
receiving leukotriene modifiers seems to be related to
unmasking of an underlying vasculitic syndrome that is
initially clinically recognized as moderate to severe asthma
and treated with corticosteroids.31Y33 However, leukotriene
modifierYassociated Churg-Strauss syndrome was reported in
steroid-naive asthmatics34 and in a patient with no recent use
of oral steroids.35 In addition, a patient with CSS who
experienced a clinical relapse after treatment with montelukast
was reported by Solans et al.36 These data may suggest an
allergic response to the drug.
Almost 150 cases of LRA-associated CSS have been
reported by the US Food and Drug Administration until
2001.37 In addition, a summary of 24 cases suggested an
association of CSS with LRA.38 In a recently reported series
of cases, however, a history of exposure to a LRA preceded
the CSS-related symptoms in only 13 of 23 patients, and the
time of disease progression from asthma to CSS was not af-
fected by the exposure.39 The youngest reported patient with
CSS after a prolonged course of montelukast was 7 years old.14
Conen et al40 reported a case of CSS in an asthmatic
patient who developed severe obstructive symptoms and
progressive heart failure after 2 sequential exposures to
montelukast. The time course of events strongly suggested a
direct etiologic role for the drug. They tried to explain the
mechanism by which LRAs might have caused the eosinophilic
vasculitis, but it remained unclear. Hypersensitivity reactions
tend to cause a leukocytoclastic rather than a granulomatous
vasculitis. Therefore, a hypersensitivity reaction to LRAs seems
unlikely. Leukotriene B4 (LTB4), a powerful chemoattractant of
eosinophils, is not inhibited by LRAs.41 This could lead to
increased plasma levels of LTB4 and trigger eosinophilic
inflammation. However, CSS has also been reported in
association with inhibitors of 5-lipoxygenase (eg, zileuton),
which also block LTB4.31
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On the other hand, 7 cases of complete and incomplete
forms of CSS not related to LRAs were reported by Bili et al,42
who concluded that CSS can happen even in patients with mild
asthma using only inhaled corticosteroids. Although safe in
most patients, asthmatic patients who are prescribed LRAs
should be monitored carefully.40,43 The previously described
steroid-sparing effect of LRAs is controversial because a
randomized controlled trial revealed that corticosteroids
cannot be reduced in patients with persistent moderate to
severe asthma despite administration of LRAs.44
Carbamazepine45 and macrolide antibiotics46 are other
drugs that have been implicated as provocative causes of
CSS. In addition, some environmental factors seem to
provoke transient effects that resemble the disease but do
not represent a chronic and self-perpetuating disease. The
inhalation of fungal spores, such as those produced by
Actinomyces and Aspergillus species, has been implicated in
the pathogenesis of some cases. Exposure to pigeons and the
molds associated with their roosts may provoke the
development of CSS.20 Smoking of free-base cocaine was
documented as a circumstance preceding individual bouts of
an illness identical to CSS.47
CLINICAL PICTURE
Three stages have been described in the clinical
evolution of CSS. The typical prodromal phase involves
allergic rhinitis and asthma (usually without family history of
atopy) that can be protracted for many years. The second
includes peripheral eosinophilia and eosinophilic tissue
infiltration. The hallmark of the final phase is systemic
vasculitis, which if left untreated, can be fatal. It may involve
the skin, lungs, musculoskeletal structures, gastrointestinal
tract, kidneys, and central and peripheral nervous systems.4,48
The first phase usually lasts for 3 to 10 years before the
development of systemic vasculitis.7 In other words, asthma is
just the presenting manifestation of CSS that is actually a
systemic vasculitic disorder.
Pulmonary disease is a central feature of CSS, and the
reported range of pulmonary manifestations in childhood is
widening. It may take the form of transitory patchy or
diffuse pulmonary infiltrates, nodular infiltrates, or pleural
effusion, often with high fever and severe systemic
manifestations.4,5,7Y9,11,15,48Y51 Eosinophilic pleural effusion
was the first clue to the diagnosis of CSS in a 16-year-old
adolescent girl.4 Eosinophils in a pleural effusion are
nonspecific and can be found in various conditions including
trauma, pneumothorax, malignancy, congestive heart failure,
infections, and rheumatologic conditions.52,53 Although
rare, CSS should be considered in the differential diagnosis
of an eosinophilic effusion.54 Less common pulmonary
manifestations include hemoptysis,7 chest pain, and pul-
monary infarction.9
Cardiovascular disease occurs in approximately half of
the patients with CSS, irrespective of age.4 Specific cardiac
involvement in CSS includes pericarditis and, less commonly,
tamponade and myocarditis.9 Congestive heart failure/
myocardial infarction accounted for 48% of all deaths in 1
series.48 Severe cardiomyopathy,51 occasionally with peri-
cardial effusion,7 has been reported in children and was fatal
in a case.19 All patients with CSS should be screened for
signs of cardiac involvement.4
Skin manifestations are a common early presentation of
CSS in childhood. They range from discrete to diffuse patchy,
petechial, or purpuric lesions and can be itchy, edematous, or
tender.9,13,15,51 A 12-year-old child with CSS experienced
typical cutaneous manifestations including palpable purpura,
skin nodules, urticarial rash, and rare lesions, such as finger tip
vesicles, infiltrated papules, and aseptic pustules.7
The most common neurological manifestation of CSS is
mononeuritis multiplex. Initial mononeuritic findings often
progress to asymmetrical polyneuropathy, which is restricted
to the limbs. Both motor and sensory deficits are detectable,
especially in the legs. Sensory disturbances may include
hypoesthesia or hyperesthesia, allodynia, and pain.20,30
Cranial nerve palsies develop infrequently.7,48,50,55 Vasculitis
of muscle develops in slightly more than 20% of patients.
Childhood-onset CSS is less likely to be complicated by
central nervous system (CNS) vasculitis than cases that
develop in middle-aged individuals.20 One girl with CSS, who
was in the early years of the second decade of her life,
developed chorea.56
Some nonrespiratory symptoms, such as paresthesia and
acalculous cholecystitis, in a patient with asthma should alert
the physician to consider the possibility of CSS.57 Renal
involvement in CSS is usually benign and rarely progresses to
renal failure. Two documented cases of renal disease and 2
with proteinuria were encountered among 10 reported
pediatric patients,5 but this was less frequent in the more
recent reports.
In addition to clinical features seen in adults, reported
symptoms in children included testicular pain, hypertension,
and seizures.58 More subtle presentations of CSS in children
include discrete cervical lymphadenopathy,6 acute abdominal
pain,8 deep venous thrombosis,9 multiple colonic ulcers,10
sudden painless loss of vision with bilateral optic neuropathy
and retinal artery occlusions,17 and oral ulceration.59 Some
rare instances of limited CSS that involved allergic granulo-
matosis and angiitis in the absence of asthma and blood
eosinophilia were reported.60,61
DIAGNOSIS
The American College of Rheumatology developed
criteria for the diagnosis of CSS in 1990. The presence of 4 or
more of these 6 criteria yielded a sensitivity of 85% and a
specificity of 99.7%62:
1. Asthma: history of wheezing or diffuse high-pitched
expiratory rhonchi.
2. Eosinophilia: greater than 10% on differential white blood
cell count.
3. Mononeuropathy or polyneuropathy: development of
mononeuropathy, multiple mononeuropathies, or poly-
neuropathy (glove/stocking distribution) attributable to
systemic vasculitis.
4. Pulmonary infiltrates that are nonfixed: migratory or
transitory pulmonary infiltrates attributable to vasculitis.
5. Paranasal sinus abnormality: history of acute or chronic
paranasal sinus pain or tenderness or radiographic
opacification of the paranasal sinuses.
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6. Extravascular eosinophils: biopsy including artery,
arteriole, or venule showing accumulations of eosino-
phils in extravascular areas.
A classification tree was also constructed with 3
selected criteria: asthma, eosinophilia greater than 10% on
differential white blood cell count, and history of documented
allergy other than asthma or drug sensitivity. For the tree
classification, the sensitivity was 95%, and the specificity was
99.2%.62
The 1994 Chapel Hill Consensus definitions aimed to
reach a consensus on the names of the major noninfectious
vasculitides and provided working definitions of 10 different
types of vasculitis based principally on the size of the affected
vessel. Churg-Strauss syndrome is classified with Wegener
granulomatosis under small-vessel necrotizing vasculitis.63
From a series of 16 patients and a review of literature on
138 patients, Lanham et al48 proposed diagnostic criteria for
CSS involving asthma, eosinophilia in excess of 1.5  109/L,
and systemic vasculitis involving 2 or more extrapulmonary
sites. Mean values for absolute eosinophil counts are in the
range of 5000 to 9000/mL, but in rare instances, counts may
exceed 100,000/mL. Treatment of asthmatic manifestations of
the first stage of CSS with corticosteroids may obscure this
characteristic finding. The prompt resolution of eosinophilia
with corticosteroid treatment is itself quite characteristic of
CSS, and the intermittent elevations of eosinophil counts
during the third phase of the disease may presage a relapse of
systemic vasculitis.20
A high index of suspicion is a key to the diagnosis of CSS
in childhood. Specifically, evidence of neuropathy or cardio-
myopathy in conjunction with a previous history of asthma and
sinusitis should alert the practitioner to this diagnosis even in
children and young adults.4 Of the diagnostic laboratory
criteria, only ANCA seems to be significantly different
between children and adults. Nearly half of the adults with
CSS are positive for ANCA.50 In contrast, neither of 2 patients
described in 1 report4 was positive for ANCA, nor did 9 of 10
children in a pediatric series.3
The concentration of ANCA may be used to monitor
disease activity and assist decision making related to
therapeutic dose reduction. The addition of monitoring levels
of antibodies to specific neutrophil enzymesVsuch as elastase,
proteinase 3, or MPOVmay enhance the reliability of ANCA
changes in predicting changes in disease activity. Anti-MPO
antibodies are characteristic in CSS (associated with p-ANCA),
whereas antiYproteinase 3 (PR3) are more specific for Wegener
granulomatosis (associated with c-ANCA).64 Animal model
studies provided some evidence of a direct pathogenic effect of
passively transferred MPO and proteinase 3Yspecific ANCAs in
inducing pauci-immune glomerulonephritis and vasculitis.65,66
In its active state, CSS may be associated with
markedly increased levels of soluble IL-2 receptor, eosinophil
cationic protein, and soluble thrombomodulin, indicating
T-cell and eosinophil activation.67 Serum IgE concentrations
are elevated in three quarters of patients in the second or
third phase. Erythrocyte sedimentation rate and other indices
suggestive of the presence of acute-phase reactants may be
also elevated.20
Chest radiographs demonstrate pulmonary infiltrates
in at least half of the patients in the second phase of
Churg-Strauss disease and a greater percentage in the third
phase of the disease. The areas of consolidation can be
symmetric or asymmetric and may have a peripheral distribu-
tion similar to that seen in chronic eosinophilic pneumonia.
Less common manifestations include small or large nodules,
unilateral or bilateral pleural effusions, and hilar lymphadeno-
pathy.48,68,69 Lungs may be hyperinflated. Nonsegmental
reticulonodular opacities without cavitation may be found.
Bronchial walls may be thickened, and enlarged intrapulmon-
ary lymph nodes may be found in some cases.20
High-resolution computed tomography frequently
demonstrates bilateral ground-glass opacities with or without
associated areas of consolidation.70 Increased vascular wall
caliber also may be discerned as well as enlarged hilar or
mediastinal lymph nodes representing an opportunity for
diagnostic biopsy. Imaging of the heart may reveal cardiome-
galy or pericardial effusion. Magnetic resonance imaging
(MRI) of the brain in patients with CNS manifestations may
reveal vascular territory infarction, with or without hemor-
rhage.20 Diffusion-weighted echoplanar MRI is said to detect
small and active ischemic changes not visible on conventional
MRI and may clearly discriminate cytotoxic from vasogenic
edema in patients with cerebral vasculitis or vasculopathy.71
Electrophysiological studies of peripheral nerves may
reveal deficits referable to both myelinated and unmyelinated
sensory and motor fibers, especially those subserving the
lower extremities. The absence of conduction blocks may be
helpful in distinguishing Churg-Strauss mononeuritis multi-
plex from chronic inflammatory demyelinating polyneuro-
pathy.20 Glomerulonephritis is not as common or severe as in
Wegener granulomatosis, but when present, it is usually focal
and segmental and indistinguishable from other forms of the
so-called pauci-immune (without significant tissue deposition
of immune complexes) glomerulonephritis.21
The seriousness of this disease and its impact on
longevity require tissue diagnosis and should not rely solely on
the American College of Rheumatology criteria. The latter
could potentially lead to overdiagnosis of borderline cases.
Transbronchial biopsies in young patients yield a minute
amount of tissue; therefore, it was suggested that such samples
be used to confirm a diagnosis when appropriate but should
not be used to rule the diagnosis out before a larger tissue
sample can be analyzed.4
DIFFERENTIAL DIAGNOSIS









& Allergic bronchopulmonary aspergillosis
& Strongyloidosis with hyperinfection syndrome
& Loeffler syndrome
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& Tropical pulmonary eosinophilia
& Cryoglobulinemia
& Acute mesenteric ischemia
& Crescentic glomerulonephritis
TREATMENT
Churg-Strauss syndrome patients usually respond well
to corticosteroid therapy often started in doses of 1 mg/kg per
day. The acute exacerbations usually require treatment with
high doses of steroids for several weeks.7,48 Intravenous
administration of methylprednisolone at doses of 15 mg/kg on
1 to 3 successive mornings is one of the most common initial
approaches to severe cases.21
Several trials reported benefit from cyclophosphamide,
azathioprine, and methotrexate in controlling disease progres-
sion or reducing relapse.72,73 Pulse intravenous cyclopho-
sphamide therapy in combination with corticosteroids seems
to diminish the risk for various adverse effects seen in patients
receiving oral cyclophosphamide daily.20
Plasma exchange has been tried but has not added
benefit to the treatment of patients who were treated with
prednisone or cyclophosphamide. This is based on a meta-
analysis of 140 patients with glomerulonephritis in CSS and
microscopic polyangiitis.74
Intravenous immunoglobulin was considered to be of
some value in Churg-Strauss vasculitis, but a randomized
placebo-controlled trial of 34 patients with ANCA-positive
vasculitis suggested only a transient improvement.75 A recent
review of evidence by members of the Primary Immunode-
ficiency Committee of the American Academy of Allergy,
Asthma and Immunology revealed that using intravenous
immunoglobulin in ANCA-positive vasculitis might provide
benefit with an evidence category of III and a low
recommendation strength (D). Such lack of convincing
evidence prevents a recommendation for its routine use.76
There is compelling evidence that TNF-> plays an
important role in the pathogenesis of ANCA-associated
vasculitis. Clinical trials that used TNF-> blockers in patients
with ANCA-associated vasculitis gave mixed results. Impor-
tantly, in a large-scale randomized trial, treatment with
etanercept was found ineffective and resulted in an excess of
treatment-related morbidity.77,78
Several case reports have described infliximab and
rituximab use in patients with steroid-dependent CSS.79Y81
Interferon alfa is said to exert a beneficial effect by
producing a dose-dependent decrease in the blood eosino-
phil count.82 Other medications tried include thalidomide20
in male patients, mycophenolate mofetil,83 and anti-IgE
(omalizumab) therapy.84
PROGNOSIS
A 5-factor score determining the poor prognosis in CSS
was described by Guillevin et al.72 It included renal failure, severe
proteinuria, severe gastrointestinal involvement, cardiomyo-
pathy, and CNS involvement. Short duration from the onset of
asthma to the onset of systemic vasculitis is probably another
poor prognostic factor.7 In general, as the number of systems
involved increases, a higher mortality is observed.4 In addition,
leukopenia caused by immunosuppressive therapy enhances risk
for sepsis and hence morbidity and mortality.85
Patients demonstrating a favorable response usually
retain an independent existence on steroid maintenance
therapy. The relapse rate is approximately 25% to 30%.20
Corticosteroids have significantly increased survival, which
now approaches greater than 75% at 5 years.3 The longest
reported survival is 37 years.86 Obviously, there is limited
information about survival or long-term outcome in childhood.
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